For patients with pulmonary fibrosis, enrolling in clinical trials can allow them access to investigational therapies that could potentially slow progression or enhance quality of life beyond currently available options. Participation in these trials helps drive research forward by improving understanding of pulmonary fibrosis and accelerating the development of innovative treatments.
The following are a selection of active, currently recruiting clinical trials related to pulmonary fibrosis and are based in the United States.
Featured Pulmonary Fibrosis Clinical Trials
| Study Title | Phase | Estimated Enrollment | Start Date | Estimated Completion |
|---|---|---|---|---|
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 3 | 1700 | May 2024 | May 2027 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | 3 | 1092 | October 2023 | December 2027 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | 3 | 1185 | September 2023 | October 2026 |
| Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 3 | 698 | October 2023 | November 2027 |
| WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | 2 | 164 | May 2025 | August 2027 |
Currently Recruiting Clinical Trials for Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Sponsor: Boehringer Ingelheim
- Goal: The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast.
- Intervention: BI 1015550
- Primary Outcome Measure: Occurrence of any adverse event over the course of the extension trial (yes/no) i.e. up until the follow-up/end of study visit planned at the latest at week 99.
- Timeframe: Up to 99 weeks and 3 days.
- Study Details
- Source
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
- Sponsor: Bristol-Myers Squibb
- Goal: The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Interventions: BMS-986278, BMS-986278 Placebo
- Primary Outcome Measures: Number of participants that experience spontaneous syncopal events; Absolute change from baseline in forced vital capacity (FVC) measured in mL.
- Timeframes: At approximately 4 weeks; At week 52.
- Study Details
- Source
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
- Sponsor: Bristol-Myers Squibb
- Goal: The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Interventions: BMS-986278, BMS-986278 Placebo
- Primary Outcome Measures: Number of participants that experience spontaneous syncopal events; Absolute change from baseline in forced vital capacity (FVC) measured in mL.
- Timeframes: At approximately 4 weeks; Up to week 52.
- Study Details
- Source
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Sponsor: United Therapeutics
- Goal: To evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
- Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Primary Outcome Measure: Change in absolute FVC from baseline to week 52.
- Timeframe: Baseline to week 52.
- Study Details
- Source
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Sponsor: Mediar Therapeutics
- Goal: A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF).
- Interventions: MTX-463, Placebo
- Primary Outcome Measure: To assess the effect of MTX-463 on the change from Baseline in forced vital capacity (FVC).
- Timeframe: 24 weeks
- Study Details
- Source
Related Guidelines:
- Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in Adults
- American Thoracic Society/European Respiratory Society, February 2022
- Treatment of Idiopathic Pulmonary Fibrosis
- American Thoracic Society, February 2022
- Diagnosis of Idiopathic Pulmonary Fibrosis
- American Thoracic Society/European Respiratory Society, June 2018
Sign up for alerts and stay informed on more clinical trials and the latest published guidelines they affect.
Copyright © 2025 Guideline Central, all rights reserved.